PAIN trial: phase II, single-center, double-blinded RCT comparing the efficacy of high dose of liposomal bupivacaine and standard bupivacaine periarticular injection in relieving immediate postoperative pain after total knee arthroplasty. Study protocol.

Juan Sebastian Vargas Hernandez, Fabiana Patricia Morosini Perez, Maria Julia Minetto, Gustavo Costa Baumgratz Lopes,Faissal Nemer Hajar,Thiago Artioli, Luis Jesús López Aboytes,Rand A. Alattar, Pablo Ignacio Carreno Montenegro,Cesar Caverzan, Nadeem Asghar Cheema, Fernanda Cruvinel de Abreu,Nervana Elbakary,Ahmed K.J Elnajjar, Salma Elnour Mohamed, Rayyan Abdulaziz Attya Fadel, Jael Garrido Dominguez,Daniela Goyes, Roberta Rossi Grudtner, Felix Hofmann, Murillo Macedo Lobo Filho, Jessica Monteiro Machado, Winnie Mathur,Heba Jamaluddin Mominkhan, Atamai Caetano Moraes, Daniel Silva Nogueira, Federico Javier Nunez Ricardo, Ronan Jose Vieira Neto,Maham Zahid,Tristan Mirko Struja,Laura A. Downey, Uruguay. Centro Hospitalario Pereira Rossell. Montevideo, Chile. Clínica Alemana de Santiago. Santiago, Mohak Bariatrics, Colombia. Fundacíon Clínica Shaio. Bogota

Principles and Practice of Clinical Research Journal(2020)

引用 0|浏览3
暂无评分
摘要
Introduction: Anesthetic strategies to improve postoperative pain management after Total Knee Arthroplasty (TKA) include multimodal pain management to minimize opiate requirements. Postoperatively, subcutaneous standard bupivacaine HCl is often used. Recent studies have suggested that high dose liposomal bupivacaine may result in improved outcomes. Objectives: This study aims to compare periarticular injection of 399mg (high dose) Liposomal Bupivacaine to Standard Bupivacaine in patients undergoing Total Knee Arthroplasty. Methods: We propose a phase II, single-institution, randomized, controlled, double-blinded, superiority trial with two parallel arms with a 1:1 allocation ratio. The two arms of the study will be standard bupivacaine and liposomal bupivacaine at 399mg dose. We will include patients with age >50 years, with primary knee osteoarthritis requiring TKA, ASA status 1 and 2, without opioid consumption in the last 3 months, and with signed informed consent. Exclusion criteria are history of substance abuse, uncontrolled psychiatric disorder, hepatic cirrhosis, renal failure, rheumatoid arthritis, immune arthritis, post-traumatic osteoarthritis, active malignancy or oncologic disease, pregnancy, synchronic surgical intervention, and morbid obesity with Body Mass Index (BMI) equal or greater than 40kg/m2. The primary outcome is time to first opioid rescue. Secondary outcomes include total opioid consumption, VAS scale, adverse events, GROC score, arc of motion, bupivacaine serum levels, length of stay, and mobilization. Discussion: Improving total knee arthroplasty postoperative pain without opioids decreases opioid-related side effects, reduces costs, and improves outcomes. By decreasing opiate use and complications related to them, Liposomal Bupivacaine may improve patient satisfaction as well as functional outcomes.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要